← Back to headlines
Novartis Secures Licensing Deal Worth Up to $1.8 Billion for Oral Peptide Drugs
Novartis has entered into a licensing agreement potentially worth up to $1.8 billion for oral peptide drugs.
18 Feb, 14:21 — 18 Feb, 14:21
Novartis has entered into a licensing agreement potentially worth up to $1.8 billion for oral peptide drugs.
18 Feb, 14:21 — 18 Feb, 14:21